BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 3034055)

  • 1. Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma.
    Nonomura A; Ohta G; Hayashi M; Izumi R; Watanabe K; Takayanagi N; Mizukami Y; Matsubara F
    Am J Gastroenterol; 1987 Jun; 82(6):512-8. PubMed ID: 3034055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of ras oncogene p21 product and proliferating cell nuclear antigen in liver cirrhosis and the correlation with liver cell dysplasia].
    Feng Z; He R; Lu Z; Ling Y
    Zhonghua Gan Zang Bing Za Zhi; 2000 Dec; 8(6):343-5. PubMed ID: 11135691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of ras and c-myc oncoproteins and hepatitis B surface antigen in human liver disease.
    Tiniakos D; Spandidos DA; Yiagnisis M; Tiniakos G
    Hepatogastroenterology; 1993 Feb; 40(1):37-40. PubMed ID: 8462926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ras oncogene p21 expression in hepatocellular carcinoma.
    Jagirdar J; Nonomura A; Patil J; Thor A; Paronetto F
    J Exp Pathol; 1989; 4(1):37-46. PubMed ID: 2550600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver.
    Masaki T; Tokuda M; Yoshida S; Nakai S; Morishita A; Uchida N; Funaki T; Kita Y; Funakoshi F; Nonomura T; Himoto T; Deguchi A; Kimura Y; Izuishi K; Wakabayashi H; Usuki H; Yoshiji H; Watanabe S; Kurokohchi K; Kuriyama S
    Int J Oncol; 2005 Mar; 26(3):661-71. PubMed ID: 15703821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues.
    Tiniakos D; Spandidos DA; Kakkanas A; Pintzas A; Pollice L; Tiniakos G
    Anticancer Res; 1989; 9(3):715-21. PubMed ID: 2548435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological characteristics of surgically resected minute hepatocellular carcinomas.
    Maeda T; Takenaka K; Taguchi K; Kajiyama K; Shirabe K; Shimada M; Tsuneyoshi M; Sugimachi K
    Hepatogastroenterology; 2000; 47(32):498-503. PubMed ID: 10791221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver cell dysplasia in liver cirrhosis and hepatocellular carcinoma.
    Szczepański W
    Pol J Pathol; 1997; 48(3):147-57. PubMed ID: 9401407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric DNA analysis of cirrhotic liver cells in patients with hepatocellular carcinoma can provide a new prognostic factor.
    Ruà S; Comino A; Fruttero A; Torchio P; Bouzari H; Taraglio S; Torchio B; Capussotti L
    Cancer; 1996 Sep; 78(6):1195-202. PubMed ID: 8826940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.
    Daveau M; Scotte M; François A; Coulouarn C; Ros G; Tallet Y; Hiron M; Hellot MF; Salier JP
    Mol Carcinog; 2003 Mar; 36(3):130-41. PubMed ID: 12619035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Nardone G; Romano M; Calabrò A; Pedone PV; de Sio I; Persico M; Budillon G; Bruni CB; Riccio A; Zarrilli R
    Hepatology; 1996 Jun; 23(6):1304-12. PubMed ID: 8675143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.
    Yeh MM; Larson AM; Campbell JS; Fausto N; Rulyak SJ; Swanson PE
    Am J Surg Pathol; 2007 May; 31(5):681-9. PubMed ID: 17460450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell biological evaluation of liver cell carcinoma, dysplasia and adenoma by tissue micro-array analysis.
    van Dekken H; Verhoef C; Wink J; van Marion R; Vissers KJ; Hop WC; de Man RA; IJzermans JN; van Eijck CH; Zondervan PE
    Acta Histochem; 2005; 107(3):161-71. PubMed ID: 16000213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
    Tátrai P
    Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathomorphologic comparison of hepatitis C virus-related and hepatitis B virus-related cirrhosis bearing hepatocellular carcinoma.
    Kojiro M; Shimamatsu K; Kage M
    Princess Takamatsu Symp; 1995; 25():179-84. PubMed ID: 8875623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Determination of expression of eight p53-related genes in hepatocellular carcinoma with tissue microarrays].
    Zhu MH; Ni CR; Zhu Z; Li FM; Zhang SM
    Ai Zheng; 2003 Jul; 22(7):680-5. PubMed ID: 12866955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of p53, Bcl-2, and hMSH2 protein expression in the cirrhotic, macroregenerative, dysplastic nodules and hepatocellular carcinomas in Upper Egypt.
    Hussein MR
    Liver Int; 2004 Dec; 24(6):552-60. PubMed ID: 15566504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?
    Kara B; Doran F; Kara IO; Akkiz H; Sandikci M
    Int J Clin Pract; 2008 Aug; 62(8):1206-11. PubMed ID: 18284441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy.
    Ohguchi S; Nakatsukasa H; Higashi T; Ashida K; Nouso K; Ishizaki M; Hino N; Kobayashi Y; Uematsu S; Tsuji T
    Hepatology; 1998 Feb; 27(2):599-607. PubMed ID: 9462663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.